BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26430163)

  • 1. Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer.
    Forsberg LA; Rasi C; Pekar G; Davies H; Piotrowski A; Absher D; Razzaghian HR; Ambicka A; Halaszka K; Przewoźnik M; Kruczak A; Mandava G; Pasupulati S; Hacker J; Prakash KR; Dasari RC; Lau J; Penagos-Tafurt N; Olofsson HM; Hallberg G; Skotnicki P; Mituś J; Skokowski J; Jankowski M; Śrutek E; Zegarski W; Tiensuu Janson E; Ryś J; Tot T; Dumanski JP
    Genome Res; 2015 Oct; 25(10):1521-35. PubMed ID: 26430163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
    Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
    Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
    Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
    J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.
    Naylor TL; Greshock J; Wang Y; Colligon T; Yu QC; Clemmer V; Zaks TZ; Weber BL
    Breast Cancer Res; 2005; 7(6):R1186-98. PubMed ID: 16457699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.
    Ronowicz A; Janaszak-Jasiecka A; Skokowski J; Madanecki P; Bartoszewski R; Bałut M; Seroczyńska B; Kochan K; Bogdan A; Butkus M; Pęksa R; Ratajska M; Kuźniacka A; Wasąg B; Gucwa M; Krzyżanowski M; Jaśkiewicz J; Jankowski Z; Forsberg L; Ochocka JR; Limon J; Crowley MR; Buckley PG; Messiaen L; Dumanski JP; Piotrowski A
    Hum Mutat; 2015 Nov; 36(11):1088-99. PubMed ID: 26219265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
    Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
    Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
    Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
    Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
    Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification.
    Courjal F; Theillet C
    Cancer Res; 1997 Oct; 57(19):4368-77. PubMed ID: 9331100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncovering the genomic heterogeneity of multifocal breast cancer.
    Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
    J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
    Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
    Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
    Szöllösi J; Balázs M; Feuerstein BG; Benz CC; Waldman FM
    Cancer Res; 1995 Nov; 55(22):5400-7. PubMed ID: 7585609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.
    Mesquita B; Lopes P; Rodrigues A; Pereira D; Afonso M; Leal C; Henrique R; Lind GE; Jerónimo C; Lothe RA; Teixeira MR
    Breast Cancer Res Treat; 2013 Feb; 138(1):37-45. PubMed ID: 23329352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.